Japanese drugmaker Eisai and US-based Biogen have been working together on advancing research in the space of Alzheimer’s for nearly a decade. Finally, the FDA, granted the fruits of that labor, Leqembi, its blessing for intravenous use. This marks the first approved treatment that can slow the progression of Alzheimer’s.
FWIW, I found this an interesting related article
https://www.science.org/content/blog-post/lilly-s-new-donanemab-data-alzheimer-s